A high WBC at diagnosis, which has traditionally been a predictor of poor response in T-ALL, has considerably weakened prognostic significance in the face of modern, more intensive chemotherapy. To test the hypothesis that bone marrow stroma-supported leukemic cell recovery might identify children at high risk for relapse, we measured the ex vivo recovery of T-ALL lymphoblasts from 29 newly diagnosed patients using a stromal cell co-culture assay. In all cases the T-ALL lymphoblasts showed an increase in recovery of T-ALL cells (RTC), ranging from 4 to 343%, in comparison to samples maintained without stroma. Since we were blinded to patient outcome in this case-control study, we then correlated patient outcome with RTC. The RTC for 18 patients in complete continuous remission (CCR) for greater than 4 years was stochastically larger than for the 11 patients who eventually relapsed (P = 0.011, by the two-sided Wilcoxon test). Furthermore, 100% of patients with an RTC of more than 26% had a CCR greater than 4 years while 78% of the patients with an RTC of less than 25% relapsed within 4 years. This is the first report to show that higher lymphoblast recovery may predict a more favorable outcome for children with T-ALL. A prospective study is needed to test whether stroma-supported leukemic cell recovery might serve as a basis for assigning risk-adjusted therapy.
Introduction
Acute lymphoblastic leukemia is the most common form of cancer in childhood, affecting approximately 2000 children per year. [1] [2] [3] T-lineage acute lymphoblastic leukemia (T-ALL) accounts for 10-15% of childhood ALL and, in some co-operative group studies, has had a less favorable prognosis in relation to precursor B-lineage ALL. [4] [5] [6] [7] Indeed, 20-50% of patients with T-ALL die from progressive disease. 4, 5, 8 Although these outcomes constitute a marked improvement relative to 30 years ago, complete remission rates and overall survival have improved only slightly over the last 5-10 years. [8] [9] [10] The development of rapid, reliable laboratory tests that predict patient prognosis may lead to enhanced patient survival. For instance, in precursor B-lineage ALL, a number of biological markers, including trisomies of chromosomes 4 and 10, DNA ploidy and several recurring non-random translocations have been found to be highly predictive of treatment-related outcomes. 11, 12 Patients with precursor B-lineage ALL may then be stratified to treatment regimens according to the prognosis indicated by these biologic markers. 3 Children with a bad ('high-risk') prognosis receive intensified therapy, and patients with lower risk prognosis receive more moderate therapy with less toxicity and have equally good outcomes. [12] [13] [14] [15] As a result, overall survival increases for all patients, and morbidity decreases for those with lower risk. In contrast, the genotypic abnormalities associated with T-ALL have not been shown to be predictive of outcome. 9, 16 Moreover, in comparison to patients with precursor B-ALL, the clinically important features of age at diagnosis, peripheral blood white count (WBC), and degree of bulky, lymphomatous disease are much less efficient predictors of outcome for children having T-ALL when treated with modern aggressive chemotherapy. 9 A number of investigators have shown that bone marrow stromal cells support the ex vivo growth and proliferation of B-lineage and myeloid leukemia cells. [17] [18] [19] Increased ex vivo survival of precursor B-lineage ALL lymphoblasts on stroma has been shown to correlate with adverse patient outcome. 17 Our laboratory has recently shown that T-ALL lymphoblasts have enhanced ex vivo survival on bone marrow (BM) stromal cells, and that the use of a BM stroma cell line HS-5 yields more reproducible results than normal BM stroma. 20 In this report, we show that the ex vivo recovery of T-ALL lymphoblasts positively correlates with patient outcome in a case-control study. These results contrast with the findings previously reported for precursor B-lineage ALL lymphoblasts, emphasizing the biological distinctions between B-and T-lineage ALL. Our findings suggest that the ex vivo T-ALL lymphoblast recovery on BM stroma may be a useful tool for risk stratification in T-ALL therapy.
Materials and methods

Patient selection and statistical methods
A T cell phenotype-directed approach was used to treat patients with T-ALL on Pediatric Oncology Group (POG) study 8704 (T-3), which was open to accrual from May 1987 until January 1992. 8 Patients with newly diagnosed T-ALL were eligible for enrollment on the study if their age was at least 1 but less than 22 years of age, and if no prior therapy had been given except for emergency radiation or less than 1 week of vincristine and prednisone. We studied cases for which an available supply of cryopreserved bone marrow was obtained at diagnosis. The details regarding treatment on POG T-ALL study 8704 have been previously described. 8 Briefly, the induction, consolidation and continuation phases of treatment were the same for all patients with the exception that, beginning in consolidation, some children were randomized to receive or not receive L-asparaginase at 25 000 units/m 2 given i.m. weekly for 20 doses. For both treatment regimens, triple intrathecal therapy (methotrexate, hydrocortisone and cytarabine) was administered for central nervous system prophylaxis. Patients presenting with an initial white blood cell count greater than 50 000 blasts/l or overt CNS disease (irrespective of white count) received 2,400 cGy of cranial irradiation during consolidation.
Sample acquisition and study design
With prior IRB approval at each participating institution, the bone marrow samples analyzed in this report were sent by overnight courier to the Stanford University Medical Center reference laboratory (Stanford, CA, USA) for immunophenotypic confirmation of T-ALL, and for cryopreservation and storage at the POG Cell Bank at St Jude Children's Research Hospital (Memphis, TN, USA). The blast population in each sample was collected by Ficoll-Hypaque centrifugation and stored in liquid nitrogen at the POG Cell Bank in concentrations ranging from 0.5 to 3.5 × 10 7 blasts/ml. The samples were transferred and maintained in liquid nitrogen in our laboratory (SW/RSL) at the University of New Mexico until utilized in the co-culture assay. After being warmed to 37°C, the patient samples were washed with serum-free media and centrifuged once prior to immediate co-culture with HS-5 monolayers. The HS-5 human stromal cell line was the kind gift of Dr Beverly Torok-Storb (University of Washington, Seattle, WA, USA). 21 Using a Wright-stained morphological review, flow cytometric data gathered by the POG immunophenotyping reference laboratory, and trypan blue dye exclusion techniques, each sample was found to be comprised of viable (95%) T-ALL lymphoblasts (70-95% of the total cells collected). After maintenance on bone marrow stromal cells, a secondary Wright-stained morphological review of each sample by an experienced hematopathologist (RSL) and characteristic flow cytometric scattergrams confirmed that Ͼ70% of each patient specimen was comprised of T-ALL lymphoblasts. 20, 22 A list of primary BM specimens from POG study 8704 was randomly selected from the electronic inventory of patients with cell bank samples. The selection was constrained to have approximately equal number of patients who relapsed after 4 years and patients who were in complete continuous remission (CCR) for at least 4 years. The list, blinded as to outcome, was sent to the POG Cell Bank, which then forwarded 46 vials to the assay laboratory. Of these, 17 were randomly used to establish the assay 20, 23 while the remaining 29 (11 cases and 18 controls) were tested and are the subject of this report. The assays were conducted in a blinded fashion, and the results forwarded to the central data center for statistical analysis. Our study represents a generous allocation of available T-ALL samples. We received 46 (16%) of the samples from the 285 eligible patients in the POG Cell Bank. In comparison, a case-control study using precursor B-ALL samples 24 received 104 of 1500 samples, or fewer than 6% of available specimens. The Cell Bank availability of samples reflects epidemiological differences in the prevalence of T-ALL vs precursor B-ALL. Note that the resulting imbalance in cases to controls had only a minor impact on statistical power. A study with 18 cases and 11 controls (n = 29) has approximately the same power as a study of 14 cases and 14 controls (n = 28).
Cell survival assay using co-cultured leukemia and HS-5 stromal cells
HS-5 has been previously shown to support hematopoiesis 21 and to give more reproducible results than normal BM marrow. 20 Using the co-culture assay, we have extended these observations to include T-ALL cell lines (SupT1) and primary patient samples. 20, 23 After completion of this study, we randomly re-tested three primary patient samples (in duplicate) and found that the recovery of T-ALL lymphoblasts on HS-5 had a coefficient of variation from the mean of less than 12% (data not shown). Briefly, SupT1 cells in log-phase growth or thawed patient-derived T-ALL samples were washed three times in serum-depleted media (RPMI supplemented with 10 mM HEPES) (Sigma, St Louis, MO, USA). A total of 5.0 × 10 5 viable T-ALL lymphoblasts were seeded on to stromal cells in 24-well flat bottom tissue culture plates (Corning, Corning, NY, USA). Stromal cell monolayers were produced by plating 5 × 10 4 cells 24 h prior to addition of Sup T1 cells or T-ALL patient samples. Stromal cells were washed three times in serum-depleted media and examined microscopically to ensure that the monolayers had remained intact. The patientderived or cell line T-ALL lymphoblasts were seeded and allowed to grow in direct contact with the HS-5 cells at 37°C in 5% CO 2 with 90% humidity. All experiments were performed in duplicate.
Modifications of the co-culture assay
Neutralizing concentrations of monoclonal antibodies (mAb) directed against LFA-1 (10 g of TS1/22), ICAM-1 (10 g of 84H10), and a non-binding isotype-matched control (5 g of LM 2/1) were purified from hybridoma lines (American Type Culture Collection, Rockville, MD, USA), 8, 25 and added to BM stroma and T-ALL cell co-culture at the beginning of the indicated experiments. In addition, T-ALL lymphoblasts were also co-cultured with HS-5 conditioned media (CM) in the absence of stroma. To produce CM, HS-5 cells were grown to greater than 80% confluency, washed three times with RPMI 1640 to remove serum, then fed with fresh serum-free media and cultured for 48 h. After centrifugation at 500 g for 10 min, the CM supernatant was collected, filtered and used immediately. The number of recovered cells was measured at 1 h and at 72 h.
Enumeration of cell survival
In order to quantify cell recovery, T-ALL lymphoblasts were harvested at 1 or 72 h post-incubation and stained by direct immunofluorescence using a fluorescently labeled mAbs directed against CD5, CD34, and CD45. 26 A gate was first set around cells with light scattering and fluorescent properties of T-ALL cells and, secondly, CD5, CD34, or CD45 dim expression was confirmed in the gated cell population. CD5 is a pan T-lineage antigen, but is not expressed on bone marrow cells (including HS-5), or myeloid, erythroid or B-lineage lymphoid precursors. CD34 is commonly expressed on lymphoblasts and was also useful in enumerating T-ALL lymphoblast recovery. In CD34-negative cases, the presence of CD45 dim was used to verify that the gated populations were not comprised of mature leukocytes. Lymphoblasts and immature marrow elements express CD45 dim . In previous studies, we have also used CD3 to verify the immunophenotypic nature of the T-ALL population. 20, 23 Flow-based lymphoblast recovery was measured by counting a gated number of events over 2. 
Statistical methods and analysis
The statistical purpose of this study was to determine, in preliminary fashion, if any of the assay components (variables) were promising as prognostic factors in T-ALL. The significant factors were documented for verification in a larger prospective study. There were five dependent variables of interest, each of which was studied by univariate methods, since we have an individual interest in each component. The major analysis compared the cases and controls, using a two-sided Wilcoxon test. 27 Due to the small number of patients and the lack of important prognostic factors in T-ALL, it was not feasible to repeat the analyses to adjust for other factors. However, for the single variable that reached statistical significance at P Ͻ 0.05, we examined the association between RTC against age and white cell count by Kendall's tau-B, the fraction of 'concordant pairs minus the fraction of discordant pairs'. 2 (Continuous variables X and Y are concordant for a given pair of assays if the patient with the higher X also has the higher Y. Otherwise, the pair is discordant. Ties in either variable are not considered.) Due to the nature of the selection of patients in this case-control design, survival analysis such as the Kaplan-Meier, Cox regression, or the log-rank test would be inappropriate.
Leukemia
Results
We enumerated T-ALL lymphoblast recovery under five conditions as described in the Materials and methods. The immunophenotype of the T-ALL cells was verified at the beginning and end of the assay in order to ensure enumeration of the correct population as described in the Materials and methods. We chose to study all five conditions in order to determine whether any of these variables were promising as prognostic factors in T-ALL. The first two assay conditions (percentage of cells recovered and growth ratio) were designed to examine measurements of total cell recovery. The percentage of recovered T-ALL cells (RTC) was determined directly from each patient-derived sample. We then normalized RTC to the recovery of a cell line (Sup T1) (growth ratio) which has been previously shown to yield highly reproducible results in the co-culture assay. 20 This means of growth normalization was designed to normalize for inter-assay differences, if necessary, and variability in stroma-supported T-ALL lymphoblast recovery. We also studied the constituent elements of the bone marrow microenvironment that were most likely to impact T-ALL cell recovery on the basis of previous observations: stromal cell produced-soluble factors and the LFA-1/ICAM-1 molecular pair.
23,28-31 Accordingly, we used serum-free, HS-5 bone marrow stromal cell-conditioned media to measure T-ALL lymphoblast recovery (SF-CR) in order to determine if soluble factors support growth in any cases, as well as to determine whether that growth was predictive of outcome. We also measured T-ALL cell recovery in the presence of mAbs directed against LFA-1 and ICAM-1 (LFA-1-CR and ICAM-1-CR, respectively), since we had previously shown that survival of T-ALL cells is dependent on LFA-1 on T-ALL cells binding to ICAM-1 on stromal cells. 23 This latter condition was established in order to determine if the population of T-ALL that may not be regulated by the normal growth controls (ie LFA-1/ICAM-1 independent) would be predictive of patient outcome. Additional mAbs were not studied due to a lack of available patient material.
The medians, quartile ranges (25th to the 75th percentiles), and P values of the T-ALL lymphoblast recovery data are shown in Table 1 . Only RTC showed a statistically significant ability to predict patient outcome (P = 0.011). T-ALL lymphoblast recovery in the presence of CM (SF-CR) was below 2% in all cases, and did not predict patient outcome. In addition, the number of cells recovered in the presence of LFA-1 or ICAM-1 mAbs (LFA-1-CR and ICAM-1-CR) was also Ͼ2% and did not predict patient outcome.
The RTC of samples from patients who relapsed within 4 years of diagnosis (failures) was smaller than those of the controls (CCR Ͼ 4 years; Table 1 and Figure 1 ). There was little overlap in results seen between the two groups. Using an empirical cut-off point of 26% to distinguish the groups, all 11 patients (100%) who failed therapy had RTC values of 25% or less. In addition, 14 of the 18 (78%) of patients who remained in CCR had RTC values greater than 25%. This discrimination rule was created after looking at the data and requires verification in a prospective study.
Although the small number of patient samples studied (n = 29) precludes a meaningful comparison with a wide array of independently important variables in T-ALL, we were able to examine the relationship of RTC to two presenting clinical and laboratory features, age and WBC (Table 2 ). There was no significant association between RTC values and age (Kendall's tau-B = −0.13, P = 0.36). There was a borderline association between RTC and WBC (Kendall's tau-B = −0.26, P = 0.058) with a trend of higher WBCs corresponding with lower RTC values.
Discussion
We took advantage of our recently established assay to study the survival of T-ALL lymphoblasts on BM stroma. 20 The purpose of the study was to determine if recovery of T-ALL lymphoblasts on BM stroma could discriminate patient outcome. Of five assay measurements, only the percentage of recovered T-ALL lymphoblasts (RTC) predicted clinical outcome: a higher RTC predicted a favorable outcome. The discrimination of outcome between the two groups is statistically strong enough to warrant further investigation in a prospective study. Greater statistical significance or discrimination would not be obtained by the study of additional samples in the current case-control study. Among two variables available for study, RTC was independent of age, but showed a borderline association with WBC. Finally, since the completion of the study, the 18 patients in CCR have been now followed for greater than 6 years, and only one patient has relapsed. This particular patient had a low RTC, further emphasizing the predictive power of this test. By measuring the recovery of T-ALL lymphoblasts under several different conditions in the co-culture assay, we can draw the following conclusions about patient-derived T-ALL lymphoblast ex vivo growth requirements. First, soluble factors derived from HS-5 conditioned media (SF-CR) do not support the ex vivo survival of T-ALL lymphoblasts in the patient population that was studied. Normal T cells are known to be recruited to sites of inflammation and to undergo clonal proliferation in response to chemokines, cytokines and other soluble factors. 28, 31 Since the T-ALL lymphoblasts studied in this report did not manifest a proliferative response to bone marrow stroma cell-derived CM, the possibility exists that soluble factor-induced growth and proliferation is dysregulated in patient-derived T-ALL lymphoblasts. In addition, normal T cells are highly dependent on adhesive molecule interactions to move through and proliferate in various tissue compartments. 32, 33 The addition of mAbs directed against LFA-1 and ICAM-1 to the co-culture system had no bearing on predicting clinical outcome, suggesting that adhesion-independent growth does not appear to be important to patient outcome. However, the uniform inhibition that these mAbs had on T-ALL lymphoblast recovery suggests the importance of LFA-1 and ICAM-1 molecular interactions on ex vivo T-ALL cell survival. Accordingly, we studied three patient samples more comprehensively and have shown that LFA-1/ICAM-1 binding to stroma is required as an early event in the complex cascade leading to T-ALL lymphoblast survival. 23 Finally, the growth ratio approximated the RTC results, an expected finding, since little inter-assay variability was anticipated in the HS-5 coculture assay. 20 Previous investigators have shown that increased recovery of precursor B-lineage ALL lymphoblasts on stroma predicted adverse patient outcome. 17 It has been hypothesized that stromal cells assist B-lineage ALL lymphoblasts in surviving chemotherapy. [17] [18] [19] 34 Thus, the probability of residual disease is higher, and patient outcome is worse. In contrast, our data show that increased recovery of T-lineage ALL lymphoblasts on stroma predicted favorable patient outcome. We speculate that in our assay the ability of T-ALL lymphoblasts to recapitulate normal interactions with stroma indicates that there is less disruption of normal growth control. Our rationale for this hypothesis is based on the following line of reasoning: first, the lymphoblasts from all 29 patients died ex vivo in the absence of stroma. Second, several previous investigators have suggested that relatively more aggressive neoplastic cells have greater independence from normal growth control. 35, 36 The least aggressive cells, which correlate with better patient survival, have the greatest ability to receive positive stromamediated signals to maintain normal growth control. In contrast, more aggressive lymphoblasts, which correlate with poor patient outcome, do not receive normalizing growth signals from the stroma, leading to decreased numbers of cell recovery. A similar set of observations has been described for the stroma-mediated growth control of CML progenitors. 37 Our hypothesis further implies that our ex vivo survival assay only partially recapitulates the marrow microenvironment needed to support T-ALL lymphoblast survival. Regardless of the biologic basis of our findings, the ex vivo survival assay promises to be a useful prognostic assay in T-ALL.
We have described a prognostically significant assay based on the recovery of bone marrow stroma-supported T-lineage ALL lymphoblasts. This T-ALL recovery assay offers potential for use in up-front, risk-directed therapy, since its results are available in 3 days, but still needs to be validated in a large prospective study. Such a study can also evaluate the independent prognostic significance of RTC, adjusted for other prognostic factors.
